Mobile

An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001

Mise à jour : Il y a 5 ans
Référence : EUCTR2006-006755-12

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To provide access to CB7630 for patients who have completed 12 cycles of abiraterone acetate treatment and continue to receive clinical benefit from such a treatment.

Critère d'inclusion

  • Hormone refractory prostate cancer

Liens